| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C13H25NO9.3H2O |
| Molecular Weight | 732.7236 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 18 / 18 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.CO[C@H]1O[C@H](CN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)[C@@H](O)[C@H](O)[C@H]1O.CO[C@H]3O[C@H](CN4C[C@H](O)[C@@H](O)[C@H](O)[C@H]4CO)[C@@H](O)[C@H](O)[C@H]3O
InChI
InChIKey=FOZFSEMFCIPOSZ-SPCKQMHLSA-N
InChI=1S/2C13H25NO9.3H2O/c2*1-22-13-12(21)11(20)10(19)7(23-13)3-14-2-6(16)9(18)8(17)5(14)4-15;;;/h2*5-13,15-21H,2-4H2,1H3;3*1H2/t2*5-,6+,7-,8-,9-,10-,11+,12-,13+;;;/m11.../s1
Camiglibose is a glucopyranoside and inhibitor of alpha-glucosidase with antihyperglycemic activity patented by Merrell Dow Pharmaceuticals. In rats, a single oral dose of Camiglibose administered simultaneously with 2 g/kg body wt sucrose resulted in a dose dependent reduction in the area under the 0- to 3-h glycemic response curve, A reduction in the glycemic response to sucrose was accompanied by reduced insulin secretion. Camiglibose was more effective against a sucrose load in streptozocin-administered rats than in control rats and was as effective after 16 daily doses as after a single dose. Doses that reduced the glycemic response to carbohydrate did not inhibit liver lysosomal a-glucosidase activity or cause lysosomal glycogen accumulation. In cynomolgus monkeys, an oral dose of 1 mg/kg Camiglibose reduced the glycemic and insulin responses to sucrose
Originator
Approval Year
PubMed
Patents
ACTIVE MOIETY
SUBSTANCE RECORD
